Correction: Dual inhibition of IGF-IR and ALK as an effective strategy to eradicate NPM-ALK⁺ T-cell lymphoma

Affiliations

• ¹ Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Unit 072, 1515 Holcombe Boulevard, Houston, TX, 77030, USA.
• ² Department of Hematology, Affiliated Hospital of the University of Nantong, Jiangsu, China.
• ³ State Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai, China.
• ⁴ Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden.
• ⁵ Department of Oncology and Pathology, Karolinska Institute, Stockholm, Sweden.
• ⁶ Depertment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
• ⁷ Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Unit 072, 1515 Holcombe Boulevard, Houston, TX, 77030, USA. hamin@mdanderson.org.
• ⁸ MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, TX, USA. hamin@mdanderson.org.